
Roche Highlights its Bispecific Antibody Portfolio Across a Range of Blood Cancers at ASH 2020
Shots: The company presented the new data of its T-cell engaging bispecific Abs, mosunetuzumab, glofitamab and cevostamab at ASH 2020, demonstrating encouraging activity across multiple […]